



15750 U.S.PTO

012104

UTILITY PATENT APPLICATION TRANSMITTAL

(only for new non-provisional applications under 37 CFR §1.53(b))

2241 10/761982 U.S.PTO



012104

Mail Stop Patent Application
Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail in an envelope addressed to Mail Stop Patent Application, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on

January 21, 2004

Date of Deposit

Bonnie Stein Bonnie Stein
Signature

EL 964823049 US

Express Mail No.

Transmitted herewith for filing is the patent application under 37 CFR 1.53(b) of:

AVENTIS DOCKET NO.: ST01021US CNT
INVENTORS: Michel TABART, et al.
TITLE: Indazole or Indole Derivatives, and Use Thereof in Human Medicine and More Particularly in Oncology

APPLICATION ELEMENTS

1. <input checked="" type="checkbox"/> *Fee Transmittal Form (<i>e.g., PTO/SB/17</i>) <i>(Submit an original and a duplicate for fee processing)</i>	Total Pages	<input type="text" value="179"/>
2. <input checked="" type="checkbox"/> Specification <i>(preferred arrangement set forth below)</i>	Total Pages	<input type="text" value="179"/>
- Descriptive title of the Invention		
- Cross References to Related Applications		
- Statement Regarding Fed sponsored R & D		
- Reference to Microfiche Appendix		
- Background of the Invention		
- Brief Summary of the Invention		
- Brief Description of the Drawings (<i>if filed</i>)		
- Detailed Description		
- Claim(s)		
- Abstract of the Disclosure		
3. <input type="checkbox"/> Drawing(s) (35 U.S.C. 113)	Total Sheets	<input type="text" value="0"/>
4. Oath or Declaration	Total Pages	<input type="text" value="2"/>
a. <input checked="" type="checkbox"/> Newly <u>unexecuted</u> (original or copy)		
b. <input type="checkbox"/> Copy from a prior application (37 CFR § 1.63(d))		
i. <input type="checkbox"/> <u>DELETION OF INVENTOR(S)</u>		
Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR §§ 1.63(d)(2) and 1.33(b).		
5. Power of Attorney	Total Pages	<input type="text"/>
a. <input type="checkbox"/> Newly executed (original or copy)		
b. <input type="checkbox"/> Copy from a prior application (37 CFR § 1.63(d))		
6. <input type="checkbox"/> Microfiche Computer Program (<i>Appendix</i>)		

7. Nucleotide and/or Amino Acid Sequence Submission

(if applicable, all necessary)

- a. Computer Readable Copy
- b. Paper Copy (identical to computer copy)
- c. Statement verifying identity of above copies

 If a **CONTINUING Application**, check appropriate box, and supply the requisite information: Continuation Divisional Continuation-in-partof prior application no: PCT/FR02/02638, filed 24 July 2002.

Examiner _____, Group/Art Unit _____.

(The cross reference has been inserted on page one of the specification).

 This application claims the benefit of **French Application No. 01 10118**, filed **July 27, 2001**. (The cross reference has been inserted on page one of the specification). **Incorporation By Reference** (useable if filing a continuation/divisional and a copy of the declaration from the prior application is enclosed.)

The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied, is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein.

ACCOMPANYING APPLICATION PARTS

- 7. Assignment Papers (*cover sheet & document(s)*)
- 8. 37 CFR §3.73(b) Statement
(when there is an assignee)
- 9. Verified English Translation Document (*if applicable*)
- 10. Information Disclosure Statement (IDS)/PTO-1449 Copies of IDS Citations
- 11. Preliminary Amendment
- 12. Return Receipt Postcard (MPEP 503)
(Should be specifically itemized)
- 13. *Small Entity Statement(s) Statement filed in prior application,
(PTO/SB/09-12) Status still proper and desired
- 14. Certified Copy of Priority Document(s)
(if foreign priority is claimed)
- 15. Other: Application Data Sheet

CORRESPONDENCE ADDRESS Customer Number or Bar Code Label**005487***(Insert Customer No. or Attach bar code label here)*Lawrence L. Martin, Reg. No. 46,902
Attorney/Agent for Applicant

Aventis Pharmaceuticals Inc.
Patent Department
Route #202-206 / P.O. Box 6800
Bridgewater, New Jersey 08807-0800
Telephone (908) 231-4803
Telefax (908) 231-2626
Aventis Docket No. **ST01021US CNT**

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

FEE TRANSMITTAL for FY 2004

Patent fees are subject to annual revision.

 Applicant claims small entity status. See 37 CFR 1.27**TOTAL AMOUNT OF PAYMENT** (\$ 1040)**Complete if Known**

Application Number	N t Yet Assigned
Filing Date	Filed C ncurr ntly H r with
First Named Inventor	Mich TABART, tal
Examiner Name	T B Assigned
Group / Art Unit	T B Assigned
Attorney Docket No.	ST01021US CNT

METHOD OF PAYMENT (check all that apply)
 Check Credit Card Money Order Other None
 Deposit Account

Deposit Account Number **18-1982**
 Deposit Account Name **Aventis Pharmaceuticals Inc.**

The Commissioner is authorized to: (check all that apply)

Charge fee(s) indicated below Credit any overpayments
 Charge any additional fee(s) during the pendency of this application
 Charge fee(s) indicated below, except for the filing fee to the above-identified deposit account

FEE CALCULATION**1. BASIC FILING FEE**

Large Entity	Small Entity	Fee Description	Fee Paid
Fee Code	Fee Code	Fee (\$)	Fee (\$)
1001	2001	770	770
1002	2002	340	
1003	2003	530	
1004	2004	770	
1005	2005	160	
SUBTOTAL (1)		(\$770)	

2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE

	Extra Claims	Fee from below	Fee Paid
Total Claims	35	-20** = 15	x 18 = 270
Independent	3	- 3** = 0	x 86 = 0
Claims			
Multiple Dependent			=
SUBTOTAL (2)		(\$270)	

**or number previously paid, if greater; For Reissues, see above

FEE CALCULATION (continued)**3. ADDITIONAL FEES**

Large Entity	Small Entity	Fee Description	Fee Paid
Fee Code	Fee Code	Fee (\$)	Fee (\$)
1051	2051	130	65
1052	2052	50	25
1053	2053	130	130
1812	1812	2,520	2,520
1804	1804	920*	920*
1805	1805	1,840*	1,840*
1251	2251	110	55
1252	2252	420	205
1253	2253	950	465
1254	2254	1,480	725
1255	2255	2,010	985
1401	2401	330	160
1402	2402	330	160
1403	2403	290	140
1451	1451	1,510	1,510
1452	2452	110	55
1453	2453	1,330	650
1501	2501	1,330	650
1502	2502	480	235
1503	2503	640	315
1460	1460	130	130
1807	1807	50	50
1806	1806	180	180
8021	8021	40	40
1809	2809	770	375
1810	2810	770	375
1801	2801	770	375
1802	1802	900	900
Other fee (specify)			
*Reduced by Basic Filing Fee Paid			
SUBTOTAL (3)		(\$)	

SUBMITTED BY**Complete (If applicable)**

Name (Print/Type)	Lawrence L. Martin, Reg. No. 46,902	Registration No. (Attorney/Agent)	46,902	Telephone	(908) 231-4803
Signature	<i>Lawrence L. Martin</i>			Date	January 21, 2004

WARNING: Information in this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

This collection of information is required by 37 CFR 1.17 and 1.27. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Alexandria, VA 22313. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Aventis Pharmaceuticals Inc. template